2026/05/13
Stable ASA.P® formulation confirmed after 12 months
12 months of documented stability strengthens the development of ASA.P®…
Read moreNews
Stay up to date with the latest from Auxesis Pharma. Here you’ll find news about our research, product development, and company progress.
2026/05/12
Application Submitted to the Swedish Medical Products Agency – ASA.P® Approaches Clinical Phase
Auxesis Pharma can today announce that on 11 May 2026 the company submitted its application to the Swedish Medical Products Agency for clinical evaluation of AS…
Read more
2026/05/04
Notice of Annual General Meeting
The shareholders of AUXESIS PHARMA HOLDING AB (publ), company registration number 559195-6486, are hereby invited to attend the Annual General Meeting.…
Read more
2026/04/01
How the approval process for clinical studies works in Sweden
In Sweden, a clinical study requires approval from two independent authorities before it can begin:…
Read more
2026/03/31
Auxesis Pharma strengthens its patent portfolio – new European patent application registered
Auxesis Pharma has registered a new European patent application, strengthening the company’s intellectual property protection ahead of clinical and commercial d…
Read more
2026/03/16
Auxesis Pharma Receives Ethical Approval for Planned Clinical Study with ASA.P®
Auxesis Pharma har fått etiskt godkännande inför planerade kliniska studier med läkemedelskandidaten ASA.P®.
Read more
2026/01/05
Scientific breakthrough
During the autumn, Auxesis Pharma reached a very important scientific milestone that now lays the foundation for the next phase of our growth journey.…
Read more